New hope for liver cancer: experimental combo aims to extend life
Disease control
Not yet recruiting
This study tests whether adding the experimental drug zanzalintinib to the approved drug durvalumab can help people with advanced liver cancer live longer. It is for patients whose cancer was stable or improved after initial treatment with tremelimumab and durvalumab. About 16 ad…
Phase: PHASE2 • Sponsor: Amit Mahipal • Aim: Disease control
Last updated May 15, 2026 11:55 UTC